News | May 27, 2021
Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
The company has reported total income of Rs.826.40 crores for FY 2020-21
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
The company plans to enter the EU markets in FY22
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
Subscribe To Our Newsletter & Stay Updated
